How FDA classifies in vitro diagnostics
FDA classifies an in vitro diagnostic by matching it to a generic device type listed in the classification regulations, then reading the class assigned to that type. Each listing has an identification paragraph that describes the generic type and a classification paragraph that places it in class I, class II or class III.1
Most IVD listings sit in three parts of title 21. Part 862 sets out the classification of clinical chemistry and clinical toxicology devices in commercial distribution.1 Part 864 does the same for hematology and pathology devices, and part 866 for immunology and microbiology devices.23 An immunology and microbiology device with two or more types of use is listed in only one subpart, to avoid duplicative listings.3
What the identification paragraph does and does not settle
The identification paragraph describes a generic type in general terms. A manufacturer who submits a premarket notification under part 807 must state why the device is substantially equivalent to other devices, as required in § 807.87.1 A showing that the device is accurately described by the section title and identification provisions is insufficient on its own.2
Intended use drives the result. The alcohol test system in § 862.3040 is identified by what it measures and by the diagnostic purpose of the measurement, and it is class II.1 The same analyte measured for a different purpose can fall under a different listing or a different class.
The three classes
Class I devices are subject to general controls. Many class I IVD listings also state that the device is exempt from the premarket notification procedures in subpart E of part 807, subject to the limitations in § 862.9, § 864.9 or § 866.9.123 Examples of class I listings include the following:
- quality control material (assayed and unassayed) in § 862.1660, exempt except when intended for use in donor screening tests
- general purpose laboratory equipment labeled or promoted for a specific medical use in § 862.2050
- calculator/data processing module for clinical use in § 862.2100
- mass spectrometer for clinical use in § 862.2860
- reagents for molecular diagnostic instrument test systems in § 862.3800
- dye and chemical solution stains in § 864.1850
- general purpose reagent in § 864.4010
- microorganism differentiation and identification device in § 866.2660
- whole human plasma or serum immunological test system in § 866.5700
A small number of class I listings also carry an exemption from the current good manufacturing practice requirements of the quality management system regulation in part 820. That exemption preserves the requirements concerning records and complaint files under § 820.35. It applies to general purpose laboratory equipment labeled for a specific medical use, to dye and chemical solution stains, and to general purpose reagents that are not labeled or represented as sterile.12 The wording of these exemptions was conformed to the quality management system regulation on 4 December 2025.2
Class II devices are subject to special controls. Some older entries use the designation “performance standards”, such as the automated cell counter in § 864.5200.2 A class II listing may still carry a 510(k) exemption. The hematology quality control mixture in § 864.8625 is exempt except when intended for use in blood components.2 The glucose test system in § 862.1345 is exempt only when it is solely intended for use as a drink to test glucose tolerance.1
Class III devices require an approval under section 515 of the Federal Food, Drug, and Cosmetic Act before commercial distribution, unless an exemption has been granted under section 520(g)(2). An approval consists of FDA issuing an order approving a premarket approval application or declaring completed a product development protocol.1 Where a class III listing shows no effective date for the requirement of premarket approval, the device may be commercially distributed without a PMA order until FDA promulgates a regulation under section 515(b).2
New device types and the statutory class III default
A new device that is not substantially equivalent to a legally marketed device, introduced into commercial distribution on or after 28 May 1976, is classified by statute under section 513(f) of the act into class III. No grace period applies, and FDA must have issued an order approving a PMA or declaring completed a PDP before the device is distributed, unless the device is reclassified.1 A device formerly marketed that has been substantially altered falls within this provision.2 Where FDA codifies that classification, the regulation gives the date from which approval is required, as § 864.1860 does in stating that class III immunohistochemistry devices have required an approval under section 515 since 28 May 1976.2
One generic type across more than one class
Two listings assign class by intended use within a single regulation. Immunohistochemistry reagents and kits under § 864.1860 are class I when they give the pathologist adjunctive diagnostic information that is not ordinarily reported to the clinician as an independent finding, such as differentiation markers used to subclassify tumors. The same reagents and kits are class II when they detect or measure target analytes to provide prognostic or predictive data reported as independent diagnostic information, such as semiquantitative measurement of hormone receptors in breast cancer. Any other use places the IHC in class III, and PMA has been required for those devices since 28 May 1976.2
Analyte specific reagents under § 864.4020 follow the same pattern. They are class I by default and exempt from premarket notification. They are class II when the analyte is used in blood banking tests classified as class II. They are class III when the analyte is a component in a test for diagnosis of a contagious condition highly likely to result in a fatal outcome, such as HIV or tuberculosis, or a component in a test used in donor screening for conditions on which FDA has recommended or required testing.2
Calibrators and controls are classified separately
Part 862 treats calibrators as devices in their own right. A calibrator may be distributed separately, supplied as one component of a kit, or built in as an integral part of the instrument. All three forms are classified into class II under § 862.1150 and § 862.3200, whatever the classification of the device with which they are used.1 A device and its calibrator may therefore carry different classifications even where the calibrator is built into the device.1 Control materials follow a different path. The clinical toxicology control material in § 862.3280 and the clinical chemistry quality control material in § 862.1660 are class I.1
Limitations on the 510(k) exemptions
The exemption from premarket notification for a generic type of class I or class II device extends only so far as the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that type. For IVDs, the exemption extends only so far as misdiagnosis from using the device would not be associated with high morbidity or mortality.1 A premarket notification is still required where the device is intended for a use different from that of the legally marketed device of that type, including a shift from professional use to lay use. It is also required where the modified device operates using a different fundamental scientific technology, such as detecting infectious agents by DNA probe or nucleic acid hybridization rather than culture or immunoassay.2
A premarket notification is also required for an in vitro device intended for any of the following:
- diagnosis, monitoring or screening of neoplastic diseases, with the exception of immunohistochemical devices
- screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism
- measuring an analyte that serves as a surrogate marker for screening, diagnosis or monitoring of life-threatening diseases, or to monitor therapy
- assessing the risk of cardiovascular diseases
- use in diabetes management
- identifying or inferring the identity of a microorganism directly from clinical material
- detection of antibodies to microorganisms other than IgG, or IgG assays where results are not qualitative, are used to determine immunity, or are intended for matrices other than serum or plasma
- noninvasive testing as defined in § 812.3(k)
- near patient testing (point of care)
These limitations appear in identical terms in § 862.9, § 864.9 and § 866.9.123
What special controls look like in practice
Special controls take two forms in these parts. Some listings name an FDA guidance document as the special control, such as the newborn screening test system using tandem mass spectrometry in § 862.1055 and the drug metabolizing enzyme genotyping system in § 862.3360.1 The antimicrobial susceptibility system in § 866.1645 and the gastrointestinal microorganism multiplex assay in § 866.3990 also rest on named guidance.3
Other listings codify the special controls in the regulation text. The integrated continuous glucose monitoring system in § 862.1355 sets numerical accuracy thresholds. For iCGM measurements below 70 mg/dL, the percentage within ±15 mg/dL of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 85 percent.1 The whole slide imaging system in § 864.3700 and the blood establishment computer software in § 864.9165 carry detailed design, testing and labeling controls in the regulation itself.2
Questions people also ask
What are the three device classes and what does each require?
Class I devices are subject to general controls, and many class I IVD types are exempt from premarket notification. Class II devices are subject to special controls, which may be a named FDA guidance document or requirements written into the classification regulation. Class III devices require an approval under section 515 of the act before commercial distribution, in the form of an order approving a PMA or declaring a PDP completed.1
Does a class I listing mean no 510(k) is ever needed?
A class I listing carries a 510(k) exemption only where the regulation says so, and the exemption is bounded by § 862.9, § 864.9 or § 866.9. A premarket notification remains required where the intended use differs from that of the legally marketed devices of that type, where the device uses a different fundamental scientific technology, or where the device falls into one of the nine in vitro categories listed in paragraph (c) of those sections.2
How is an IVD handled when no generic type matches it?
A device introduced on or after 28 May 1976 that is not substantially equivalent to a legally marketed device is classified into class III by section 513(f) of the act, without a grace period. FDA must have issued an order approving a PMA or declaring completed a PDP before the device is commercially distributed, unless the device is reclassified.1
Is a calibrator classified with the assay it supports?
No. Calibrators are classified into class II under § 862.1150 and § 862.3200, whether they are distributed separately, supplied within a kit or built into the instrument. The classification of the device with which the calibrator is used has no bearing on the calibrator’s own class.1
Can a single classification regulation cover more than one class?
Yes. Immunohistochemistry reagents and kits under § 864.1860 span class I, class II and class III according to the diagnostic role of the result. Analyte specific reagents under § 864.4020 span the same three classes according to the test in which the analyte is used.2
Footnotes
-
21 CFR Part 862, Clinical Chemistry and Clinical Toxicology Devices. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-862 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19
-
21 CFR Part 864, Hematology and Pathology Devices. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-864 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17
-
21 CFR Part 866, Immunology and Microbiology Devices. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-866 ↩ ↩2 ↩3 ↩4 ↩5
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.